Johnson Controls International plc — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Johnson Controls International plc filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2015 | Sep 25, 2015 | $9.90B | Nov 13, 2015 |
| FY2015 | Sep 26, 2014 | $10.33B | Nov 13, 2015 |
| FY2015 | Sep 27, 2013 | $10.06B | Nov 13, 2015 |
| FY2014 | Sep 28, 2012 | $9.89B | Nov 14, 2014 |
| FY2011 | Sep 30, 2011 | $4.69B | Nov 16, 2011 |
| FY2011 | Jun 24, 2011 | $4.29B | Nov 16, 2011 |
| FY2011 | Mar 25, 2011 | $3.99B | Nov 16, 2011 |
| FY2011 | Dec 24, 2010 | $4.38B | Nov 16, 2011 |
| FY2011 | Sep 24, 2010 | $4.49B | Nov 16, 2011 |
| FY2011 | Jun 25, 2010 | $4.27B | Nov 16, 2011 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $23.60B | Nov 14, 2025 |
| FY2025 | Sep 30, 2024 | $22.95B | Nov 14, 2025 |
| FY2025 | Sep 30, 2023 | $22.33B | Nov 14, 2025 |
| FY2024 | Sep 30, 2022 | $20.64B | Nov 19, 2024 |
| FY2023 | Sep 30, 2021 | $23.67B | Dec 14, 2023 |
| FY2022 | Sep 30, 2020 | $22.32B | Nov 15, 2022 |
| FY2021 | Sep 30, 2019 | $23.97B | Nov 15, 2021 |
| FY2020 | Sep 30, 2018 | $23.40B | Nov 16, 2020 |
| FY2019 | Sep 30, 2017 | $22.84B | Nov 21, 2019 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Sep 30, 2018 | $31.40B | Nov 20, 2018 |
| FY2018 | Sep 30, 2017 | $30.17B | Nov 20, 2018 |
| FY2018 | Sep 30, 2016 | $20.84B | Nov 20, 2018 |
| FY2017 | Sep 30, 2015 | $17.10B | Nov 21, 2017 |
| FY2016 | Sep 30, 2014 | $38.75B | Nov 23, 2016 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $8.59B | Nov 14, 2025 |
| FY2025 | Sep 30, 2024 | $8.08B | Nov 14, 2025 |
| FY2025 | Sep 30, 2023 | $7.80B | Nov 14, 2025 |
| FY2024 | Sep 30, 2022 | $7.09B | Nov 19, 2024 |
| FY2023 | Sep 30, 2021 | $8.06B | Dec 14, 2023 |
| FY2022 | Sep 30, 2020 | $7.41B | Nov 15, 2022 |
| FY2021 | Sep 30, 2019 | $7.69B | Nov 15, 2021 |
| FY2020 | Sep 30, 2018 | $7.67B | Nov 16, 2020 |
| FY2019 | Sep 30, 2017 | $7.53B | Nov 21, 2019 |
| FY2018 | Sep 30, 2016 | $5.65B | Nov 20, 2018 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $3.29B | Nov 14, 2025 |
| FY2025 | Sep 30, 2024 | $1.71B | Nov 14, 2025 |
| FY2025 | Sep 30, 2023 | $1.85B | Nov 14, 2025 |
| FY2024 | Sep 30, 2022 | $1.53B | Nov 19, 2024 |
| FY2023 | Sep 30, 2021 | $1.64B | Dec 14, 2023 |
| FY2022 | Sep 30, 2020 | $631.00M | Nov 15, 2022 |
| FY2021 | Sep 30, 2019 | $5.67B | Nov 15, 2021 |
| FY2020 | Sep 30, 2018 | $2.16B | Nov 16, 2020 |
| FY2019 | Sep 30, 2017 | $1.61B | Nov 21, 2019 |
| FY2018 | Sep 30, 2016 | ($868.00M) | Nov 20, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2015 | Sep 25, 2015 | $884.00M | Nov 13, 2015 |
| FY2015 | Sep 26, 2014 | $700.00M | Nov 13, 2015 |
| FY2015 | Sep 27, 2013 | $712.00M | Nov 13, 2015 |
| FY2014 | Sep 28, 2012 | $578.00M | Nov 14, 2014 |
| FY2013 | Sep 30, 2011 | $982.00M | Nov 14, 2013 |
| FY2012 | Sep 24, 2010 | $615.00M | Nov 16, 2012 |
| FY2011 | Sep 25, 2009 | ($1.51B) | Nov 16, 2011 |
| FY2010 | Sep 26, 2008 | $1.90B | Nov 12, 2010 |
| FY2009 | Sep 28, 2007 | ($1.73B) | Nov 17, 2009 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $273.00M | Nov 14, 2025 |
| FY2025 | Sep 30, 2024 | $267.00M | Nov 14, 2025 |
| FY2025 | Sep 30, 2023 | $251.00M | Nov 14, 2025 |
| FY2024 | Sep 30, 2022 | $236.00M | Nov 19, 2024 |
| FY2023 | Sep 30, 2021 | $275.00M | Dec 14, 2023 |
| FY2022 | Sep 30, 2020 | $274.00M | Nov 15, 2022 |
| FY2021 | Sep 30, 2019 | $319.00M | Nov 15, 2021 |
| FY2020 | Sep 30, 2018 | $310.00M | Nov 16, 2020 |
| FY2019 | Sep 30, 2017 | $307.00M | Nov 21, 2019 |
| FY2018 | Sep 30, 2016 | $158.00M | Nov 20, 2018 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $5.76B | Nov 14, 2025 |
| FY2025 | Sep 30, 2024 | $5.66B | Nov 14, 2025 |
| FY2025 | Sep 30, 2023 | $5.39B | Nov 14, 2025 |
| FY2024 | Sep 30, 2022 | $5.08B | Nov 19, 2024 |
| FY2023 | Sep 30, 2021 | $5.26B | Dec 14, 2023 |
| FY2022 | Sep 30, 2020 | $5.67B | Nov 15, 2022 |
| FY2021 | Sep 30, 2019 | $6.24B | Nov 15, 2021 |
| FY2020 | Sep 30, 2018 | $5.64B | Nov 16, 2020 |
| FY2019 | Sep 30, 2017 | $5.72B | Nov 21, 2019 |
| FY2018 | Sep 30, 2016 | $4.19B | Nov 20, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Sep 30, 2021 | $2.55B | Nov 15, 2021 |
| FY2021 | Sep 30, 2020 | $2.48B | Nov 15, 2021 |
| FY2021 | Sep 30, 2019 | $1.74B | Nov 15, 2021 |
| FY2020 | Sep 30, 2018 | $1.52B | Nov 16, 2020 |
| FY2019 | Sep 30, 2017 | $371.00M | Nov 21, 2019 |
| FY2018 | Sep 30, 2016 | $1.91B | Nov 20, 2018 |
| FY2017 | Sep 30, 2015 | $1.60B | Nov 21, 2017 |
| FY2016 | Sep 30, 2014 | $2.40B | Nov 23, 2016 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $37.94B | Nov 14, 2025 |
| FY2025 | Sep 30, 2024 | $42.70B | Nov 14, 2025 |
| FY2024 | Sep 30, 2023 | $42.24B | Nov 19, 2024 |
| FY2024 | Sep 30, 2022 | $42.16B | Nov 19, 2024 |
| FY2023 | Sep 30, 2021 | $41.89B | Dec 14, 2023 |
| FY2022 | Sep 30, 2020 | $40.82B | Nov 15, 2022 |
| FY2021 | Sep 30, 2019 | $42.29B | Nov 15, 2021 |
| FY2020 | Sep 30, 2018 | $48.80B | Nov 16, 2020 |
| FY2019 | Sep 30, 2017 | $51.88B | Nov 21, 2019 |
| FY2018 | Sep 30, 2016 | $63.18B | Nov 20, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2015 | Sep 25, 2015 | $8.25B | Nov 13, 2015 |
| FY2015 | Sep 26, 2014 | $7.13B | Nov 13, 2015 |
| FY2014 | Sep 27, 2013 | $7.04B | Nov 14, 2014 |
| FY2013 | Sep 28, 2012 | $7.34B | Nov 14, 2013 |
| FY2012 | Sep 30, 2011 | $12.46B | Nov 16, 2012 |
| FY2011 | Sep 24, 2010 | $13.03B | Nov 16, 2011 |
| FY2010 | Sep 25, 2009 | $12.60B | Nov 12, 2010 |
| FY2009 | Sep 26, 2008 | $13.30B | Nov 17, 2009 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $12.93B | Nov 14, 2025 |
| FY2025 | Sep 30, 2024 | $16.10B | Nov 14, 2025 |
| FY2024 | Sep 30, 2023 | $16.55B | Nov 19, 2024 |
| FY2023 | Sep 30, 2022 | $16.27B | Dec 14, 2023 |
| FY2022 | Sep 30, 2021 | $17.56B | Nov 15, 2022 |
| FY2021 | Sep 30, 2020 | $17.45B | Nov 15, 2021 |
| FY2021 | Sep 30, 2019 | $19.77B | Nov 15, 2021 |
| FY2021 | Sep 30, 2018 | $21.16B | Nov 15, 2021 |
| FY2020 | Sep 30, 2017 | $20.45B | Nov 16, 2020 |
| FY2019 | Sep 30, 2016 | $24.12B | Nov 21, 2019 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $16.63B | Nov 14, 2025 |
| FY2025 | Sep 30, 2024 | $16.73B | Nov 14, 2025 |
| FY2025 | Sep 30, 2023 | $16.77B | Nov 14, 2025 |
| FY2024 | Sep 30, 2022 | $16.18B | Nov 19, 2024 |
| FY2023 | Sep 30, 2021 | $18.34B | Dec 14, 2023 |
| FY2022 | Sep 30, 2020 | $17.93B | Nov 15, 2022 |
| FY2021 | Sep 30, 2019 | $18.18B | Nov 15, 2021 |
| FY2020 | Sep 30, 2018 | $18.38B | Nov 16, 2020 |
| FY2019 | Sep 30, 2017 | $18.59B | Nov 21, 2019 |
| FY2018 | Sep 30, 2016 | $21.02B | Nov 20, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $0 | Nov 14, 2025 |
| FY2025 | Sep 30, 2024 | $848.00M | Nov 14, 2025 |
| FY2024 | Sep 30, 2023 | $1.38B | Nov 19, 2024 |
| FY2023 | Sep 30, 2022 | $1.15B | Dec 14, 2023 |
| FY2022 | Sep 30, 2021 | $2.03B | Nov 15, 2022 |
| FY2021 | Sep 30, 2020 | $2.47B | Nov 15, 2021 |
| FY2020 | Sep 30, 2019 | $4.83B | Nov 16, 2020 |
| FY2019 | Sep 30, 2018 | $6.60B | Nov 21, 2019 |
| FY2018 | Sep 30, 2017 | $5.23B | Nov 20, 2018 |
| FY2017 | Sep 30, 2016 | $9.18B | Nov 21, 2017 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $379.00M | Nov 14, 2025 |
| FY2025 | Sep 30, 2024 | $606.00M | Nov 14, 2025 |
| FY2025 | Sep 30, 2023 | $828.00M | Nov 14, 2025 |
| FY2024 | Sep 30, 2022 | $2.03B | Nov 19, 2024 |
| FY2023 | Sep 30, 2021 | $1.34B | Dec 14, 2023 |
| FY2022 | Sep 30, 2020 | $1.95B | Nov 15, 2022 |
| FY2021 | Sep 30, 2019 | $2.81B | Nov 15, 2021 |
| FY2020 | Sep 30, 2018 | $185.00M | Nov 16, 2020 |
| FY2019 | Sep 30, 2017 | $301.00M | Nov 21, 2019 |
| FY2018 | Sep 30, 2016 | $579.00M | Nov 20, 2018 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $9.20B | Nov 14, 2025 |
| FY2025 | Sep 30, 2024 | $8.57B | Nov 14, 2025 |
| FY2024 | Sep 30, 2023 | $8.46B | Nov 19, 2024 |
| FY2015 | Sep 25, 2015 | $3.15B | Nov 13, 2015 |
| FY2015 | Sep 26, 2014 | $1.46B | Nov 13, 2015 |
| FY2014 | Sep 27, 2013 | $1.46B | Nov 14, 2014 |
| FY2013 | Sep 28, 2012 | $1.49B | Nov 14, 2013 |
| FY2012 | Sep 30, 2011 | $4.11B | Nov 16, 2012 |
| FY2011 | Sep 24, 2010 | $4.19B | Nov 16, 2011 |
| FY2010 | Sep 25, 2009 | $4.27B | Nov 12, 2010 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | 5 | Nov 14, 2025 |
| FY2025 | Sep 30, 2024 | 2 | Nov 14, 2025 |
| FY2025 | Sep 30, 2023 | 2 | Nov 14, 2025 |
| FY2024 | Sep 30, 2022 | 2 | Nov 19, 2024 |
| FY2023 | Sep 30, 2021 | 2 | Dec 14, 2023 |
| FY2022 | Sep 30, 2020 | 0 | Nov 15, 2022 |
| FY2021 | Sep 30, 2019 | 6 | Nov 15, 2021 |
| FY2020 | Sep 30, 2018 | 2 | Nov 16, 2020 |
| FY2019 | Sep 30, 2017 | 1 | Nov 21, 2019 |
| FY2018 | Sep 30, 2016 | (1) | Nov 20, 2018 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | 5 | Nov 14, 2025 |
| FY2025 | Sep 30, 2024 | 2 | Nov 14, 2025 |
| FY2025 | Sep 30, 2023 | 2 | Nov 14, 2025 |
| FY2024 | Sep 30, 2022 | 2 | Nov 19, 2024 |
| FY2023 | Sep 30, 2021 | 2 | Dec 14, 2023 |
| FY2022 | Sep 30, 2020 | 0 | Nov 15, 2022 |
| FY2021 | Sep 30, 2019 | 6 | Nov 15, 2021 |
| FY2020 | Sep 30, 2018 | 2 | Nov 16, 2020 |
| FY2019 | Sep 30, 2017 | 1 | Nov 21, 2019 |
| FY2018 | Sep 30, 2016 | (1) | Nov 20, 2018 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Sep 2, 2016 | 935.50M | Nov 20, 2018 |
| FY2009 | Sep 25, 2009 | 479.35M | Nov 17, 2009 |
Dividends Paid
Cash dividends distributed to common shareholders during the period. Shown as a positive value despite being a cash outflow in the SEC filing.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $976.00M | Nov 14, 2025 |
| FY2025 | Sep 30, 2024 | $1.00B | Nov 14, 2025 |
| FY2025 | Sep 30, 2023 | $980.00M | Nov 14, 2025 |
| FY2024 | Sep 30, 2022 | $916.00M | Nov 19, 2024 |
| FY2023 | Sep 30, 2021 | $762.00M | Dec 14, 2023 |
| FY2022 | Sep 30, 2020 | $790.00M | Nov 15, 2022 |